Answers are grounded in this paper and cite their sources.
Most guidelines call for the discontinuation of treatment with tumor necrosis factor blockers in patients who develop tuberculosis. We report a case of life-threatening tuberculosis paradoxical reaction involving the lungs caused by withdrawal of the anti-tumor necrosis factor antibody adalimumab. Clinical improvement occurred only after resumption of adalimumab treatment.
No takes yet. Share an insight, caveat, or question.
Wallis et al. (2009) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: